26th October 2022
Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment
The 37th Annual European Association of Urology (EAU) Congress 2022 in Amsterdam, the Netherlands, where data from the CLEAR study, a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab combination therapy against sunitinib as first-line treatment in patients with advanced renal cell carcinoma, were presented.
25th October 2022
Striving for more: personalizing care in patients with psoriatic disease
Striving for more: personalizing care in palients with psoriatic disease. Educational objectives: Understand what patients need and expect from their treatment journey from its outset. Drive the importance of collecting patient reported outcomes on registries and analysing data by gender/age. Consider shared decision-making as essential throughout a patient’s joumey, understanding how it can further treatment personalisation and patient outcomes
13th October 2022
Current challenges and future perspectives in Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis
As part of Novartis’ continued commitment to medical education in rheumatology. We Invite you to our faculty as they discuss: -The disease state of JPsA and ERA and the impact of diagnosis, clinical features, and disease activity on patients and caregivers. -The importance of both the patient perspective and the unmet needs for optimizing the management of JPsA and ERA -Clinical evidence for IL17 inhibition in the management of ERA and JPsA.
8th September 2022
World AD Day: Progress in patient care and beyond
This video, featuring Professor Stephan Weidinger, celebrates the progress made in the way diseases such as atopic dermatitis are managed via the topic of patient care transformation, as well as the importance of inspiring action to maintain the momentum needed to continue to advance towards multidisciplinary care.